[lofatdairy]

I appreciate the links but I think this actually misses the point. The novelty isn't in diagnosis of cancer but in sensitivity/cost-efficacy in detection of known biomarkers for breast cancer (and associated risks of recurrence, etc). I'm not familiar with how common ELISA-based HER2 testing takes place, but it seems like it has some impact on drug decisions[^1].

In terms of applicability, it depends on whether or not ELISA is in fact the current standard of care, but it could be useful in low-resource settings where you don't have lab personnel trained to carry out those assays, and drug choice is also restricted by limited availability.

Additionally, there's a point-of-care argument as well. Since breast cancer does benefit from early detection, I can see a future in which biomarker testing is a more regular thing, and high saliva concentrations are flagged. At the very least as something worth bringing up at one's next appointment or wtv.

[^1]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033231/

[tetramer]

The standard of care in the US is immunohistochemistry (IHC), with FISH testing in equivocal cases so not really ELISA based.

HER2 testing is done on all breast cancers as it affects treatment choices though the majority of breast cancers are not HER2 positive. (HER2 is also expressed in some normal tissue (notably cardiac) and is also seen in other cancers as well).